Muscular Dystrophies

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

Defining Endpoints in Becker Muscular Dystrophy

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

VirtualPark_Pediatric

ECoG BMI for Motor and Speech Control

A Multi-Dimensional Model of cAre and transItion for Patients With cOmplex RAre Diseases

Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders

Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders

Muscle Health Measurements Using Electrical Impedance Myography

Pro-inflammatory Cytokines in Facioscapulohumeral Muscular Dystrophy (CYTOKINE-FSH)

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)